Lactobacillus crispatus

What is Lactobacillus crispatus?

L. crispatus is a common protective bacterium in healthy vaginal and urinary bacterial communities. Lower abundance is associated with bacterial vaginosis, E. coli colonization, and recurrent UTIs. These associations led to research on specific probiotic strains.

Other names and forms it’s sold as

• CTV-05 / Lactin-V: the intravaginal strain with the real UTI trial data (a biotherapeutic, not a supplement)
• LMG S-29995: the strain in positive oral BV trials
• Generic “L. crispatus” in supplement blends: often with strain identifiers (Lcr86, etc.) that appear in no clinical literature

Where does it come from?

It’s an endogenous human commensal; most women host it naturally in vagina and periurethra. Supplement strains are cultured isolates, typically of dairy-fermentation origin, and not necessarily vaginal-adapted.

How does it work in the body?

L. crispatus acidifies its niche via lactic acid, produces hydrogen peroxide and bacteriocins, and competitively excludes urinary pathogens. The 2022 PNAS mechanism paper added a new piece: L. crispatus triggers type-I interferon in bladder epithelial cells, boosting their capacity to kill intracellular E. coli. Direct evidence that bladder-resident lactobacilli are protective, and the strongest scientific basis for the “urinary microbiome” supplement thesis.

That finding also carries the caveat: the protection comes from lactobacilli already resident in the bladder. Whether an oral capsule can install them there is a different question, with a negative answer so far.

What is it claimed to do?

Prevent recurrent UTIs, restore vaginal flora after antibiotics, prevent BV, and, in microbiome-framed bladder products, “repopulate the urinary microbiome” to reduce leaks and urgency.

What does the research show?

The main ingredient trial — and its delivery caveat

Stapleton et al. (2011, J Infect Dis): 100 premenopausal women with recurrent UTI received intravaginal Lactin-V or placebo after antibiotic treatment. Recurrent UTI: 15% vs 27% (RR ~0.5); among women who sustained high-level L. crispatus colonization, the relative risk dropped to 0.07. A 2021 phase-2 cystitis trial (GAI 98322 strain, vaginal suppository) reported 86% responder rate sustained a year after stopping.

The oral route — promising for vagina, unproven for bladder

An oral combination of L. crispatus LMG S-29995 + L. brevis + L. acidophilus (5.4 billion CFU/day) cut BV recurrence to 18.3% vs 32.1% (p = .014): real evidence that oral dosing can shift vaginal flora. But the urinary tract is the step further: Wolff et al.’s double-blind trial gave women 3 months of oral GR-1/RC-14 and found no change in urinary lactobacilli and no detection of the probiotic strains in urine at all.

Strain specificity — the detail labels bury

All positive trials used named, vaginal-adapted strains (CTV-05, GAI 98322, LMG S-29995). Commercial blends carry deposit numbers like “Lcr86” with zero published human data. Probiotic effects are strain-specific by consensus definition; the species name on a label is a promise the strain may not keep.

What doesn’t L. crispatus do?

It hasn’t been shown to treat active UTI or BV (adjunct-to-antibiotics only), reduce urgency or leakage in any trial, or colonize the bladder from an oral capsule. The urinary-microbiome-to-incontinence link it rides on is associational: different bacterial populations correlate with continence status; no intervention has proven causation.

What dose was studied?

Note the unit: all dosing is in CFU (colony-forming units), not milligrams. A label listing a probiotic blend in mg, with no CFU figure, hasn’t disclosed the only quantity that predicts whether it works.

Side effects

Among the safest ingredients in any formula; decades of trials report no serious adverse events in healthy women. Immunocompromised patients have rare case reports of bloodstream infection (a class-level probiotic caution, not specific to this species).

Drug interactions

• Antibiotics: take the probiotic hours apart or after the course (antibiotics kill it); several trials specifically dose post-antibiotic
• Immunosuppressants: theoretical infection risk in severely immunocompromised patients

Who should not take it?

Severely immunocompromised people (chemotherapy, high-dose steroids, central lines: the standard probiotic caution). Everyone else, including pregnant women, has clean safety data in trials.

What the authorities say

ISAPP’s consensus (Hill et al., Nat Rev Gastroenterol Hepatol 2014) defines probiotics as strain-specific: benefits attach to the strain and dose studied, not the species generally. NCCIH rates lactobacilli safe for healthy people and cautions for the immunocompromised. L. crispatus specifically is an investigational live biotherapeutic (Lactin-V) in FDA-tracked trials: recognition that this species is real medicine-adjacent, delivered by route and strain, not by name alone.

What to know about Lactobacillus crispatus

The strongest recurrent-UTI evidence used vaginal L. crispatus CTV-05, not an oral capsule. Oral-to-bladder colonization remains unestablished. Strain identity and a live-bacteria count are necessary to assess whether any product matches the cited studies.